![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SPX |
Gene summary for SPX |
![]() |
Gene information | Species | Human | Gene symbol | SPX | Gene ID | 80763 |
Gene name | spexin hormone | |
Gene Alias | C12orf39 | |
Cytomap | 12p12.1 | |
Gene Type | protein-coding | GO ID | GO:0002027 | UniProtAcc | Q9BT56 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80763 | SPX | HCC1_Meng | Human | Liver | HCC | 6.83e-21 | 7.67e-02 | 0.0246 |
80763 | SPX | HCC1 | Human | Liver | HCC | 5.10e-04 | 9.88e-01 | 0.5336 |
80763 | SPX | HCC2 | Human | Liver | HCC | 2.91e-02 | 9.75e-01 | 0.5341 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166722 | Liver | HCC | response to nutrient levels | 276/7958 | 474/18723 | 2.30e-12 | 1.08e-10 | 276 |
GO:001087621 | Liver | HCC | lipid localization | 228/7958 | 448/18723 | 1.80e-04 | 1.41e-03 | 228 |
GO:0044539 | Liver | HCC | long-chain fatty acid import into cell | 14/7958 | 17/18723 | 9.39e-04 | 5.47e-03 | 14 |
GO:0140354 | Liver | HCC | lipid import into cell | 14/7958 | 17/18723 | 9.39e-04 | 5.47e-03 | 14 |
GO:000686921 | Liver | HCC | lipid transport | 198/7958 | 398/18723 | 1.92e-03 | 9.78e-03 | 198 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPX | SNV | Missense_Mutation | novel | c.272N>T | p.Ser91Phe | p.S91F | Q9BT56 | protein_coding | tolerated(0.23) | benign(0.021) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPX | SNV | Missense_Mutation | c.31N>G | p.Thr11Ala | p.T11A | Q9BT56 | protein_coding | tolerated(0.66) | benign(0) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
SPX | SNV | Missense_Mutation | c.301A>C | p.Lys101Gln | p.K101Q | Q9BT56 | protein_coding | deleterious(0.04) | benign(0.058) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SPX | SNV | Missense_Mutation | c.155N>A | p.Arg52His | p.R52H | Q9BT56 | protein_coding | tolerated(0.06) | possibly_damaging(0.495) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SPX | SNV | Missense_Mutation | c.67N>G | p.Asn23Asp | p.N23D | Q9BT56 | protein_coding | tolerated(0.23) | benign(0.003) | TCGA-AY-6196-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
SPX | SNV | Missense_Mutation | c.171N>T | p.Gln57His | p.Q57H | Q9BT56 | protein_coding | tolerated(0.12) | benign(0.01) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |
SPX | SNV | Missense_Mutation | rs201207493 | c.205N>T | p.Pro69Ser | p.P69S | Q9BT56 | protein_coding | tolerated(0.57) | benign(0.286) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
SPX | SNV | Missense_Mutation | novel | c.289G>A | p.Glu97Lys | p.E97K | Q9BT56 | protein_coding | deleterious(0.04) | benign(0.019) | TCGA-AG-A014-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SPX | SNV | Missense_Mutation | c.171N>T | p.Gln57His | p.Q57H | Q9BT56 | protein_coding | tolerated(0.12) | benign(0.01) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SPX | SNV | Missense_Mutation | novel | c.53N>G | p.Phe18Cys | p.F18C | Q9BT56 | protein_coding | deleterious(0.05) | benign(0) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |